BioVaxys and Horizon Technology Update Asset Purchase Agreement in Major Move for Immunotherapies

BioVaxys Executes Key Amendment with Horizon Technology

In a significant strategic move, BioVaxys Technology Corp. (CSE: BIOV, FRA: 5LB) has announced an amendment to its Asset Purchase Agreement (APA) with Horizon Technology Finance Corporation. This update pertains to the acquisition of assets and intellectual properties connected to the DPX™ immune-educating technology platform developed by IMV Inc., a Canadian biotechnology firm.

Background of the Agreement

The original APA, formalized on February 11, 2024, included a performance milestone requiring BioVaxys to secure $10 million in capital by December 31, 2024. However, adjustments have been made to this stipulation over the past months. Initially, on December 9, 2024, both parties agreed to extend the deadline to June 30, 2025, but this was further revised following ongoing evaluations of BioVaxys’ financial landscape.

On May 28, 2025, a subsequent amendment to the original agreement adjusted the required capital to $2,028,636, acknowledging the evolving situation around funding accessibility in the biotech sector. The most recent amendment, executed on September 25, 2025, further lowered the milestone to $1,785,625. This is a crucial adjustment as it reflects the challenges companies like BioVaxys face in raising capital within a dynamic economic environment. If BioVaxys meets this new target by September 30, 2026, Section 12 of the APA will be rendered inactive.

Implications of the Amendments

These amendments signify not just shifts in financial targets, but a broader response to the pressures of securing adequate funding for ongoing research and development initiatives. BioVaxys, focused on fostering innovative immunotherapies to combat various cancers and diseases, continually adapts its strategy to align with market conditions.

With products in clinical development, including maveropepimut-S (MVP-S), targeting conditions like relapsed-refractory Diffuse Large B Cell Lymphoma (DLBCL) and platinum-resistant ovarian cancer, the strategic adjustments underscore the company’s agility in navigating the professional landscape of biopharmaceuticals. MVP-S leverages the DPX™ platform to orchestrate an immune response specific to survivin, a protein prevalent in numerous aggressive cancers, proving its potential effectiveness.

Moreover, BioVaxys is exploring additional innovative projects, such as the DPX™+SurMAGE immunotherapy, aiming to elicit responses to multiple cancer-targeting proteins simultaneously, showcasing its commitment to advancing cancer treatment methodologies.

About BioVaxys Technology Corp.

The company, based in British Columbia, Canada, is dedicated to improving patient outcomes through the development of novel immunotherapies. With its team of experts and diverse clinical pipelines, BioVaxys stands at the forefront of cancer treatment innovation. By continuing to hone its approach and adapt to funding challenges, the firm remains focused on delivering impactful healthcare solutions.

BioVaxys's shares are publicly traded on the CSE under the ticker symbol BIOV and are available on the Frankfurt Bourse (FRA: 5LB) and OTC Markets in the U.S. as BVAXF. For further insights and updates, stakeholders can visit BioVaxys and connect with them on social platforms like X and LinkedIn.

Conclusion

This recent amendment serves as a pivotal moment for BioVaxys, highlighting its resilience and forward-thinking approach in critical financial and operational dimensions. Stakeholders, investors, and biotech enthusiasts will keenly observe how this strategy unfolds and its potential impact on the company's future priorities and projects.